Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Interprofessional Relations | 5 | 2020 | 1013 | 1.52 | Why? |
| Sofosbuvir | 3 | 2020 | 518 | 1.31 | Why? |
| Cooperative Behavior | 3 | 2020 | 1216 | 0.89 | Why? |
| Fluorenes | 1 | 2020 | 101 | 0.81 | Why? |
| Ranitidine | 1 | 2018 | 27 | 0.74 | Why? |
| GABA-A Receptor Agonists | 1 | 2017 | 6 | 0.71 | Why? |
| Anemia, Hemolytic | 1 | 2019 | 70 | 0.70 | Why? |
| Peptic Ulcer | 1 | 2018 | 85 | 0.69 | Why? |
| Benzimidazoles | 1 | 2020 | 275 | 0.69 | Why? |
| Nicolau Syndrome | 1 | 2017 | 38 | 0.69 | Why? |
| Methylprednisolone Hemisuccinate | 1 | 2017 | 20 | 0.68 | Why? |
| Health Occupations | 1 | 2020 | 235 | 0.68 | Why? |
| Pentoxifylline | 1 | 2018 | 80 | 0.68 | Why? |
| Pressure Ulcer | 2 | 2021 | 398 | 0.61 | Why? |
| Enteral Nutrition | 2 | 2018 | 320 | 0.61 | Why? |
| Interdisciplinary Communication | 2 | 2020 | 1425 | 0.60 | Why? |
| Penicillins | 1 | 2017 | 132 | 0.59 | Why? |
| Vasodilator Agents | 1 | 2018 | 344 | 0.58 | Why? |
| Consciousness Disorders | 1 | 2017 | 335 | 0.55 | Why? |
| Malaria, Falciparum | 1 | 2019 | 377 | 0.54 | Why? |
| Faculty, Medical | 1 | 2020 | 595 | 0.53 | Why? |
| Education, Professional | 1 | 2014 | 128 | 0.45 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 1510 | 0.45 | Why? |
| Pyridines | 1 | 2017 | 680 | 0.44 | Why? |
| Pneumonia, Bacterial | 1 | 2018 | 843 | 0.44 | Why? |
| Pneumonia, Ventilator-Associated | 1 | 2018 | 861 | 0.41 | Why? |
| Isoniazid | 1 | 2010 | 105 | 0.39 | Why? |
| Enoxaparin | 3 | 2021 | 1064 | 0.39 | Why? |
| Health Personnel | 4 | 2020 | 29646 | 0.37 | Why? |
| Atazanavir Sulfate | 2 | 2020 | 213 | 0.36 | Why? |
| Interferon beta-1a | 2 | 2021 | 316 | 0.34 | Why? |
| Antiviral Agents | 9 | 2021 | 41703 | 0.34 | Why? |
| Antimalarials | 1 | 2019 | 2505 | 0.31 | Why? |
| Cardiovascular Agents | 1 | 2012 | 663 | 0.31 | Why? |
| Patient Care Team | 1 | 2020 | 3556 | 0.31 | Why? |
| Iran | 9 | 2021 | 5467 | 0.30 | Why? |
| Antitubercular Agents | 1 | 2010 | 775 | 0.25 | Why? |
| Nifedipine | 1 | 2021 | 27 | 0.23 | Why? |
| Drug Combinations | 3 | 2020 | 3852 | 0.22 | Why? |
| Hydroxychloroquine | 3 | 2021 | 12447 | 0.21 | Why? |
| Glucocorticoids | 1 | 2017 | 4431 | 0.21 | Why? |
| Thrombolytic Therapy | 1 | 2012 | 2218 | 0.21 | Why? |
| Pneumonia, Viral | 11 | 2020 | 243684 | 0.21 | Why? |
| Coronavirus Infections | 11 | 2020 | 253789 | 0.20 | Why? |
| Sulbactam | 1 | 2018 | 37 | 0.19 | Why? |
| Education, Distance | 1 | 2020 | 4956 | 0.19 | Why? |
| Treatment Outcome | 11 | 2021 | 51732 | 0.19 | Why? |
| Ampicillin | 1 | 2018 | 73 | 0.19 | Why? |
| Critical Illness | 4 | 2020 | 17281 | 0.18 | Why? |
| Physical Therapy Specialty | 1 | 2019 | 69 | 0.18 | Why? |
| Magnesium Sulfate | 1 | 2018 | 52 | 0.18 | Why? |
| Valerian | 1 | 2017 | 2 | 0.18 | Why? |
| Interferon beta-1b | 1 | 2020 | 274 | 0.17 | Why? |
| Metoclopramide | 1 | 2017 | 9 | 0.17 | Why? |
| Administration, Topical | 1 | 2018 | 272 | 0.17 | Why? |
| Double-Blind Method | 5 | 2021 | 5988 | 0.17 | Why? |
| Gastric Mucosa | 1 | 2018 | 141 | 0.17 | Why? |
| Adiponectin | 1 | 2018 | 123 | 0.17 | Why? |
| Amlodipine | 1 | 2017 | 45 | 0.17 | Why? |
| Benzoxazines | 1 | 2017 | 103 | 0.16 | Why? |
| Ankle | 1 | 2017 | 66 | 0.16 | Why? |
| Ultrasonography, Doppler, Color | 1 | 2017 | 107 | 0.16 | Why? |
| Students, Health Occupations | 1 | 2019 | 224 | 0.16 | Why? |
| Myocardial Infarction | 1 | 2012 | 3361 | 0.16 | Why? |
| Antiemetics | 1 | 2017 | 75 | 0.16 | Why? |
| Anti-Bacterial Agents | 1 | 2018 | 10083 | 0.16 | Why? |
| Referral and Consultation | 1 | 2012 | 4816 | 0.16 | Why? |
| Colistin | 1 | 2018 | 217 | 0.15 | Why? |
| Percutaneous Coronary Intervention | 1 | 2012 | 3646 | 0.15 | Why? |
| Time-to-Treatment | 1 | 2012 | 5883 | 0.15 | Why? |
| Magnesium | 1 | 2018 | 290 | 0.15 | Why? |
| Problem-Based Learning | 1 | 2020 | 363 | 0.15 | Why? |
| Ritonavir | 2 | 2020 | 4212 | 0.15 | Why? |
| Acinetobacter Infections | 1 | 2018 | 273 | 0.15 | Why? |
| Carbapenems | 1 | 2018 | 343 | 0.15 | Why? |
| Anticoagulants | 3 | 2021 | 9563 | 0.14 | Why? |
| Humans | 36 | 2021 | 930598 | 0.14 | Why? |
| Acinetobacter baumannii | 1 | 2018 | 378 | 0.14 | Why? |
| Thrombosis | 3 | 2021 | 7504 | 0.14 | Why? |
| Capacity Building | 1 | 2020 | 683 | 0.14 | Why? |
| Injections, Intramuscular | 1 | 2017 | 800 | 0.13 | Why? |
| Tuberculosis | 1 | 2010 | 2895 | 0.13 | Why? |
| Career Choice | 1 | 2019 | 498 | 0.13 | Why? |
| Pandemics | 13 | 2021 | 389249 | 0.13 | Why? |
| Edema | 1 | 2017 | 333 | 0.13 | Why? |
| Betacoronavirus | 9 | 2020 | 204454 | 0.13 | Why? |
| Streptokinase | 1 | 2012 | 19 | 0.13 | Why? |
| Drug Administration Schedule | 4 | 2021 | 2324 | 0.12 | Why? |
| Drug Interactions | 1 | 2020 | 1653 | 0.12 | Why? |
| Insulin Resistance | 1 | 2018 | 669 | 0.12 | Why? |
| Brain Injuries, Traumatic | 1 | 2017 | 381 | 0.12 | Why? |
| Middle Aged | 17 | 2021 | 270681 | 0.12 | Why? |
| Gastrointestinal Hemorrhage | 1 | 2018 | 669 | 0.11 | Why? |
| Time Factors | 7 | 2021 | 31397 | 0.11 | Why? |
| Recovery of Function | 1 | 2021 | 2461 | 0.11 | Why? |
| Biotransformation | 1 | 2010 | 74 | 0.10 | Why? |
| Acetylation | 1 | 2010 | 124 | 0.10 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 1261 | 0.10 | Why? |
| Developed Countries | 1 | 2014 | 500 | 0.10 | Why? |
| Aged | 12 | 2021 | 215776 | 0.10 | Why? |
| Male | 17 | 2021 | 367725 | 0.09 | Why? |
| Female | 17 | 2021 | 380317 | 0.09 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.09 | Why? |
| Pain | 1 | 2017 | 1084 | 0.09 | Why? |
| Outpatients | 1 | 2021 | 3417 | 0.09 | Why? |
| Oxygen Inhalation Therapy | 1 | 2021 | 3629 | 0.08 | Why? |
| Internationality | 1 | 2020 | 3297 | 0.08 | Why? |
| History, 20th Century | 1 | 2014 | 1282 | 0.08 | Why? |
| Immunotherapy | 1 | 2021 | 2421 | 0.08 | Why? |
| Hyperglycemia | 1 | 2018 | 1363 | 0.08 | Why? |
| Endoscopy, Gastrointestinal | 1 | 2018 | 1545 | 0.08 | Why? |
| Length of Stay | 4 | 2021 | 11042 | 0.08 | Why? |
| Curriculum | 1 | 2020 | 3083 | 0.08 | Why? |
| History, 21st Century | 1 | 2014 | 1849 | 0.08 | Why? |
| Odds Ratio | 2 | 2021 | 5861 | 0.08 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.07 | Why? |
| Renal Insufficiency, Chronic | 1 | 2020 | 2654 | 0.07 | Why? |
| Extracorporeal Membrane Oxygenation | 2 | 2021 | 5002 | 0.07 | Why? |
| Brain Diseases | 1 | 2017 | 1463 | 0.07 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.07 | Why? |
| Organ Transplantation | 1 | 2020 | 2616 | 0.07 | Why? |
| Longitudinal Studies | 1 | 2020 | 9893 | 0.07 | Why? |
| Hospitals, Teaching | 1 | 2012 | 1609 | 0.07 | Why? |
| Anti-HIV Agents | 1 | 2017 | 2209 | 0.07 | Why? |
| Diagnosis, Differential | 1 | 2019 | 7220 | 0.07 | Why? |
| Adult | 11 | 2021 | 244371 | 0.07 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.07 | Why? |
| Heparin | 1 | 2017 | 2600 | 0.06 | Why? |
| Intensive Care Units | 5 | 2021 | 29594 | 0.06 | Why? |
| Coronary Angiography | 1 | 2012 | 2275 | 0.06 | Why? |
| Drug Therapy, Combination | 3 | 2020 | 7268 | 0.06 | Why? |
| Attitude of Health Personnel | 1 | 2020 | 4741 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2020 | 4273 | 0.06 | Why? |
| Primary Health Care | 1 | 2020 | 4839 | 0.06 | Why? |
| Multivariate Analysis | 1 | 2012 | 5440 | 0.06 | Why? |
| Ointments | 1 | 2021 | 54 | 0.05 | Why? |
| Kaplan-Meier Estimate | 2 | 2021 | 4260 | 0.05 | Why? |
| Fibrinolytic Agents | 1 | 2012 | 1702 | 0.05 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.05 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.05 | Why? |
| Calcineurin Inhibitors | 1 | 2020 | 218 | 0.05 | Why? |
| Arrhythmias, Cardiac | 1 | 2012 | 2510 | 0.05 | Why? |
| Phenotype | 1 | 2010 | 4037 | 0.05 | Why? |
| Hemorrhage | 2 | 2021 | 3013 | 0.05 | Why? |
| Injections, Subcutaneous | 1 | 2020 | 647 | 0.04 | Why? |
| Electrocardiography | 1 | 2012 | 3957 | 0.04 | Why? |
| Risk Factors | 3 | 2018 | 71621 | 0.04 | Why? |
| Severity of Illness Index | 3 | 2020 | 48226 | 0.04 | Why? |
| Food Intolerance | 1 | 2017 | 9 | 0.04 | Why? |
| Young Adult | 5 | 2019 | 93724 | 0.04 | Why? |
| TOR Serine-Threonine Kinases | 1 | 2020 | 385 | 0.04 | Why? |
| Acute Kidney Injury | 1 | 2018 | 5762 | 0.04 | Why? |
| Logistic Models | 1 | 2012 | 9089 | 0.04 | Why? |
| Critical Care Outcomes | 1 | 2018 | 138 | 0.04 | Why? |
| Alkynes | 1 | 2017 | 98 | 0.04 | Why? |
| Gastrointestinal Motility | 1 | 2017 | 78 | 0.04 | Why? |
| Wound Healing | 1 | 2021 | 424 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 2984 | 0.04 | Why? |
| Kidney Function Tests | 1 | 2018 | 520 | 0.04 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.04 | Why? |
| Pilot Projects | 2 | 2017 | 5182 | 0.04 | Why? |
| Central Nervous System | 1 | 2020 | 701 | 0.04 | Why? |
| Prospective Studies | 3 | 2020 | 43301 | 0.03 | Why? |
| Cyclopropanes | 1 | 2017 | 332 | 0.03 | Why? |
| Energy Intake | 1 | 2017 | 323 | 0.03 | Why? |
| Infusions, Intravenous | 1 | 2018 | 1224 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.03 | Why? |
| Dyslipidemias | 1 | 2020 | 791 | 0.03 | Why? |
| Nausea | 1 | 2017 | 457 | 0.03 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2020 | 2437 | 0.03 | Why? |
| Cardiovascular System | 1 | 2020 | 750 | 0.03 | Why? |
| Cross-Sectional Studies | 3 | 2021 | 53120 | 0.03 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.03 | Why? |
| Gastrointestinal Tract | 1 | 2020 | 1113 | 0.03 | Why? |
| Vomiting | 1 | 2017 | 722 | 0.03 | Why? |
| Lung | 1 | 2020 | 31049 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2021 | 3776 | 0.03 | Why? |
| Age Factors | 1 | 2012 | 21039 | 0.03 | Why? |
| Hypnotics and Sedatives | 1 | 2017 | 624 | 0.03 | Why? |
| HIV Infections | 1 | 2017 | 11620 | 0.03 | Why? |
| Case-Control Studies | 1 | 2010 | 17671 | 0.03 | Why? |
| Hypertension | 1 | 2012 | 8895 | 0.03 | Why? |
| Animals | 1 | 2020 | 78931 | 0.03 | Why? |
| Drug Monitoring | 1 | 2018 | 1408 | 0.02 | Why? |
| Methylprednisolone | 1 | 2020 | 2107 | 0.02 | Why? |
| Biomarkers | 1 | 2012 | 23361 | 0.02 | Why? |
| Thrombocytopenia | 1 | 2021 | 2093 | 0.02 | Why? |
| Respiratory System | 1 | 2020 | 3213 | 0.02 | Why? |
| Patient Compliance | 1 | 2017 | 1468 | 0.02 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.02 | Why? |
| Kidney Diseases | 1 | 2018 | 1434 | 0.02 | Why? |
| Oseltamivir | 1 | 2010 | 583 | 0.02 | Why? |
| Hepatitis C | 1 | 2018 | 1514 | 0.02 | Why? |
| Kidney | 1 | 2020 | 3648 | 0.02 | Why? |
| Liver | 1 | 2020 | 4007 | 0.02 | Why? |
| Influenza, Human | 1 | 2010 | 10779 | 0.02 | Why? |
| Venous Thrombosis | 1 | 2021 | 2739 | 0.02 | Why? |
| Patient Selection | 1 | 2020 | 4560 | 0.02 | Why? |
| Patient Safety | 1 | 2020 | 4885 | 0.02 | Why? |
| Blood Glucose | 1 | 2018 | 3642 | 0.02 | Why? |
| Adolescent | 2 | 2010 | 86841 | 0.02 | Why? |
| Immunosuppressive Agents | 1 | 2020 | 6331 | 0.01 | Why? |
| Pulmonary Embolism | 1 | 2021 | 4775 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2020 | 10649 | 0.01 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.01 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.01 | Why? |
| Diabetes Mellitus | 1 | 2020 | 8207 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.01 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.01 | Why? |
| Stress, Psychological | 1 | 2018 | 10231 | 0.01 | Why? |
| Depression | 1 | 2017 | 14116 | 0.01 | Why? |
| Neoplasms | 1 | 2020 | 17251 | 0.01 | Why? |
| Anxiety | 1 | 2017 | 17311 | 0.01 | Why? |
| Hospitals | 1 | 2010 | 11793 | 0.01 | Why? |
| Infant | 1 | 2010 | 30274 | 0.01 | Why? |
| Child, Preschool | 1 | 2010 | 36283 | 0.00 | Why? |
| Child | 1 | 2010 | 70012 | 0.00 | Why? |
Khalili's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(221)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(138)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_